NVO241220P132000
- 0.00
- 0.000.00%
Novo-Nordisk A/S Newsroom
Why the Investor Craze for Ozempic and Rival Weight-loss Drugs May Resume Next Year
Is Novo Nordisk A/S (NVO) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Novo Nordisk's Hiring Binge Leaves Danish Firms Starved of Labor
Sector Update: Health Care Stocks Decline Monday Afternoon
Top Midday Stories: Honeywell Mulls Separation of Aerospace Business; Starbucks Expands Parental Leave for US Store Workers
Novo Nordisk's Imminent Capacity Increase Is a Significant Positive -- Market Talk
The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect
Novo Nordisk to Invest $1.2 Billion in New Plant in Denmark
Novo Nordisk Says Catalent Buyout to Close Soon as Regulatory Conditions Met
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
CFRA Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating, Announces Target Price $122
Unusual Options Activity: YMM, SHAK and Others Attract Market Bets, YMM V/OI Ratio Reaches 100.0
Latest research confirms: Novo-Nordisk A/S Ozempic is associated with a rare risk of vision loss.
① A latest study confirms that Ozempic, a star drug from the Danish pharmaceutical giant Novo-Nordisk A/S, is associated with an increased risk of a rare eye disease that leads to vision loss; ② According to an analysis by Nordic researchers of years of patient records from Denmark and Norway, diabetic patients using Ozempic are more than twice as likely to develop NAION compared to patients using another diabetes medication.
Market Whales and Their Recent Bets on NVO Options
Novo Nordisk Shares Are Trading Lower Following a Report Suggesting a Study Linked Ozempic to an Increased Risk of a Rare Form of Vision Loss.
Express News | Novo Nordisk Shares Are Trading Lower Following a Report Suggesting a Study Linked Ozempic to an Increased Risk of a Rare Form of Vision Loss
'Ozempic Link to Rare Vision Loss Risk Confirmed in Study; Risk of Eye Condition Remains Low; Patients Should Be Aware; NAION Occurs When Loss of Blood Flow Damages Optic Nerve' - Bloomberg News
Express News | "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD